According to a market report by Lucintel, the future of the global non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets. The global non-invasive cancer diagnostic market is expected to reach an estimated $199 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are the rising concerns of chronic cancer, introduction of advanced bio marker based detection methods, and supportive government initiative to promote the use of non-invasive diagnostic test.
A more
than 150-page report to understand trends, opportunity and forecast in global non-invasive
cancer diagnostic market to 2030 by therapeutics (solid tumors, blood cancer,
lung cancer, breast cancer, and others), technology (clinical chemistry,
immunochemistry, molecular diagnostics, and others), and region (North America,
Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecast that clinical chemistry is expected to witness highest growth over the
forecast period due to its various advantages, including highly sensitive, low
cost, and widespread availability.
Breast
cancer will remain the largest segment due to increasing number of breast
cancer patients around the world.
Download
sample by clicking on non-invasive
cancer diagnostic market.
North
America is expected to witness highest growth over the forecast period due to
existence of well-established health infrastructure, growing prevalence of
cancer related cases among people, and presence of key players in the region.
Precision
Therapeutics, A&G Pharmaceutical, Affymetrix, AVIVA Biosciences, BIOVIEW,
Laboratory Corporation Of America, Quest Diagnostics Incorporated Cancer
Genetics, Digene, Gen-Probe, IVDiagnostics are the major suppliers in the non-invasive cancer diagnostic market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Aflatoxin Rapid Test Kit Market
Anti-streptolysin O Assay Kit Market
Brain Function Ultrasound Imaging System Market
No comments:
Post a Comment